Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease.

Kang ChaoYibiao HuangXia ZhuJian TangXueding WangLang LinHuili GuoCaibin ZhangMiao LiQingfan YangJie HuangLingna YePinjin HuMin HuangQian CaoXiang Gao

Published in: Alimentary pharmacology & therapeutics (2021)

Among Chinese patients with Crohn's disease, dose optimisation by NUDT15 C415T reduced the rate of thiopurine-induced leucopenia, without significant influence on efficacy. Using 50% dose reduction for heterozygotes, and alternative drugs for homozygotes, are practicable strategies. Clinical trial number: NCT02929706.

Keyphrases

clinical trial
open label
double blind
study protocol
phase ii
phase iii
high glucose
gene expression
randomized controlled trial
high throughput
genome wide
placebo controlled
dna methylation
oxidative stress
genetic diversity